E34.51 Complete androgen insensitivity syndrome

Name of the Condition

• Complete Androgen Insensitivity Syndrome (ICD-10 Code: E34.51)

Summary

Complete androgen insensitivity syndrome (CAIS) is a genetic condition where individuals with XY chromosomes are completely resistant to male hormones (androgens), resulting in the development of female external genitalia despite having male internal reproductive structures. This occurs due to nonfunctional androgen receptors, preventing androgens from exerting their effects. Affected individuals typically present with normal breast development, absent or sparse pubic/axillary hair, and primary amenorrhea, requiring clinical and genetic evaluation for diagnosis.

Causes

CAIS is caused by mutations in the androgen receptor gene, which disrupts the body’s ability to respond to androgens. These mutations are typically inherited in an X-linked recessive pattern, meaning males (XY) are affected, while carrier females (XX) usually show no symptoms. The mutations lead to a complete loss of androgen receptor function, resulting in the absence of male secondary sexual characteristics and the development of female external genitalia.

Risk Factors

• Genetic mutations in the androgen receptor gene.
• Family history of androgen insensitivity syndrome or related disorders.
• Sporadic mutations in individuals with no family history.

Symptoms

• Female external genitalia at birth.
• Normal breast development during puberty.
• Absent or sparse pubic and axillary hair.
• Primary amenorrhea (absence of menstruation).
• Infertility due to lack of functional gonads (testes) or uterus.

Diagnosis

Diagnosis involves a combination of clinical evaluation, hormone testing, and genetic analysis. Physical examination may reveal female external genitalia with undescended testes. Hormone levels typically show elevated testosterone (consistent with male gonads) but no response to androgens. Genetic testing confirms mutations in the androgen receptor gene. Imaging (e.g., ultrasound) may identify internal reproductive structures, and biopsy of gonadal tissue can rule out malignancy.

Treatment Options

Management focuses on symptom relief and preventive care. Gonadectomy (removal of testes) is often recommended to reduce cancer risk, typically after puberty to allow natural breast development. Hormone replacement therapy (estrogen) may be used to support bone health and secondary sexual characteristics. Psychological support and gender-affirming care are integral to addressing psychosocial needs. Fertility is not possible, but assisted reproduction options (e.g., donor eggs) may be discussed.

Prognosis and Follow-Up

With appropriate management, individuals with CAIS can lead healthy lives. Regular follow-up includes monitoring for gonadal tumors (via imaging or tumor markers) and assessing bone density, cardiovascular health, and psychological well-being. Early diagnosis and multidisciplinary care (endocrinology, gynecology, psychology) improve outcomes. Lifelong hormone therapy may be necessary to maintain bone and metabolic health.

Complications

• Increased risk of gonadal tumors (e.g., gonadoblastoma) if gonads are not removed.
• Osteoporosis due to estrogen deficiency if hormone therapy is not initiated.
• Psychological distress related to gender identity or infertility.
• Potential cardiovascular risks from metabolic changes.

Lifestyle & Prevention

• Regular medical follow-up to monitor for complications.
• Adherence to hormone replacement therapy to support bone and metabolic health.
• Psychological counseling to address gender identity or body image concerns.
• Genetic counseling for affected individuals and their families.

When to Seek Professional Help

Seek medical attention if there are signs of ambiguous genitalia at birth, primary amenorrhea in adolescence, or unexplained infertility. Prompt evaluation is critical for early diagnosis and management. Consult a specialist (endocrinologist, geneticist) for suspected CAIS or related symptoms.

Tips for Medical Coders

Document the degree of androgen insensitivity (complete vs. partial) and any associated complications (e.g., gonadal tumors) to support accurate coding. Ensure genetic testing results or clinical notes confirm the diagnosis. Code E34.51 is specific to complete androgen insensitivity; use additional codes for related conditions (e.g., gonadal dysgenesis) if present. Verify documentation aligns with the clinical presentation to avoid miscoding.